Bharat Biotech and Dunc Minh donate 200,000 doses of COVAXIN to Vietnam

This donation represents a gesture of goodwill to provide access to Bharat Biotech’s WHO-approved, indigenously-developed COVAXIN to fight the COVID-19 pandemic across borders. COVAXIN has received Emergency Use Listing (EUL) in Vietnam.

Bharat Biotech was invited by the Embassy of Vietnam for a one-on-one meeting with the President of the National Assembly, to discuss avenues of cooperation, supplies, and technology transfer possibilities.

“It is an honour for us to serve the Republic of Vietnam in a humble manner and wish COVAXIN contribution will help boost up the country’s national vaccination program and recovery from the pandemic,” said Ella.

“We believe in vaccine equity, global public health, and having access to the vaccine is vital for national health, and I hope everyone in the Republic of Vietnam will take advantage of having access to the widely administered, safe and efficacious COVAXIN.”

Bharat Biotech has completed Phase-2 and Phase-3 trials of COVAXIN for children in the age group of 2 to 18 years. The data has been submitted to the Central Drugs Standard Control Organisation (CDSCO) and the final approval is awaited. On approval, children will also have access to COVAXIN.

In Vietnam, Bharat Biotech has been working with Duc Minh Medical JSC, towards the commercialization of INDIRAB (Inactivated Rabies Vaccine). Duc Minh is Bharat Biotech’s local partner in Vietnam.

Bharat Biotech has also supplied INDIRAB to Vietnam supporting their national rabies vaccine requirement.